Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali

计划入组 100 人 · 首次发布于 2022 年 9 月 22 日

A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines

计划入组 1,680 人 · 首次发布于 2023 年 7 月 19 日

PsA Treatment With hOKT3γ1 (Ala-Ala)

计划入组 4 人 · 首次发布于 2005 年 10 月 17 日

SpFN-ALFQ

Alao (5%)

ALAN-CE

Alar Pharmaceuticals Inc

Taiwan

Cedeño Jara Alan Joel

Ecuador

Alam, Dr Z Yasim

Canada

Phase 3 Trial Launches for Novel Triple-Drug Malaria Treatment to Combat Artemisinin Resistance

FDA Issues Untitled Letter to Alar Pharmaceuticals Over Promotion of Unapproved Ketamine Drug ALA-3000

Alar Pharmaceuticals Reports Breakthrough Phase 1 Results for Long-Acting Ketamine Injectable ALA-3000 in Treatment-Resistant Depression